| Patient | Joe Frazier |
|---|---|
| Date of birth | 1962-01-12 |
| Identifiers | MRN HR-BX004-SYN; SSN (made up) 000-04-5590 |
| Document date | 2026-11-01 |
| Author | Clarence Whitfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care for type 2 diabetes and high blood pressure above goal: A1c, kidney function, urine albumin, lipids, the yearly liver check with FIB-4, eyes, feet and brain health in a former professional boxer. Concerns: He wants to keep working at his gym and stay strong; He worries about the cost of new medicines; He wants to know whether the blows he took in the ring will affect his memory. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years | One tablet twice daily with meals | Oral route | 2026-02-16 | active | S |
| Lisinopril 20 mg oral tablet, one tablet daily; taken for years | One tablet daily | Oral route | 2026-02-16 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-16 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-04-13 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-04-13 | active | S |
| Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly | 0.25 mg weekly for four weeks, then 0.5 mg weekly | Subcutaneous route | 2026-03-02 to 2026-05-18 | completed | S |
| Semaglutide pen (1 mg per dose), 1 mg under the skin once weekly | 1 mg once weekly | Subcutaneous route | 2026-05-18 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Twelve-lead electrocardiogram | 2026-02-16 to 2026-02-16 | completed | S |
| Comprehensive diabetic foot examination with a 10-g monofilament, vibration and pulses | 2026-02-16 to 2026-02-16 | completed | S |
| Liver transient elastography with controlled attenuation parameter | 2026-03-02 to 2026-03-02 | completed | S |
| Liver ultrasound for hepatocellular carcinoma surveillance, baseline | 2026-03-02 to 2026-03-02 | completed | S |
| Upper endoscopy to screen for varices | 2026-04-06 to 2026-04-06 | completed | S |
| Dilated eye examination at the eye clinic | 2026-06-22 to 2026-06-22 | completed | S |
| Liver ultrasound for hepatocellular carcinoma surveillance, six months | 2026-09-14 to 2026-09-14 | completed | S |
| Advance care planning conversation, about 18 minutes | 2026-07-13 to 2026-07-13 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-02-16 | Tdap vaccine | completed | S |
| 2026-03-02 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-03-02 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-03-02 | Hepatitis A vaccine, adult, dose 1 of 2 | completed | S |
| 2026-04-13 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 2026-09-14 | Hepatitis A vaccine, adult, dose 2 of 2 | completed | S |
| 2026-07-13 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-09-14 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
| 2026-09-14 | Influenza vaccine, inactivated, this season | completed | S |
| 2026-09-14 | COVID-19 vaccine, mRNA, this season | completed | S |
| 2026-09-14 | RSV vaccine, single dose | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1964 | Broken left thumb in the 1964 Olympic final | D (CLM-0003) |
| 1964 | Cataract in the left eye found at 20, with reduced vision in that eye through his boxing career (20/400 in that eye by 1975) | D (CLM-0004) |
| 1965 to 1976, and one bout in 1981 | Professional heavyweight boxing career with many blows to the head, including a 1975 bout stopped when he could no longer see | D (CLM-0005, CLM-0006) |
| early 2000s | Diabetes and high blood pressure, reported publicly | D (CLM-0008) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He wants to keep working at his gym and stay strong | active | S |
| He worries about the cost of new medicines | active | S |
| He wants to know whether the blows he took in the ring will affect his memory | active | S |
Most recent measures: Hemoglobin A1c/Hemoglobin.total in Blood 6.8 on 2026-09-14; Glucose [Mass/volume] in Serum or Plasma 168 on 2026-02-16; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-09-14; Potassium [Moles/volume] in Serum or Plasma 4.5 on 2026-09-14; Creatinine [Mass/volume] in Serum or Plasma 1.06 on 2026-09-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 78 on 2026-09-14; Albumin/Creatinine [Mass Ratio] in Urine 14 on 2026-09-14; Cholesterol [Mass/volume] in Serum or Plasma 148 on 2026-04-13; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 68 on 2026-04-13; Cholesterol in HDL [Mass/volume] in Serum or Plasma 40 on 2026-04-13; Triglyceride [Mass/volume] in Serum or Plasma 168 on 2026-04-13; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 38 on 2026-09-14; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 on 2026-09-14; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 96 on 2026-02-16; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2026-09-14; Bilirubin.total [Mass/volume] in Serum or Plasma 0.8 on 2026-09-14; Hemoglobin [Mass/volume] in Blood 14.2 on 2026-02-16; Platelets [#/volume] in Blood by Automated count 140 on 2026-09-14; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 340 on 2026-02-16; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-02-16; Total score [AUDIT-C] 2 on 2026-02-16; Liver stiffness by US.transient elastography 17.6 on 2026-03-02; INR in Platelet poor plasma by Coagulation assay 1.1 on 2026-03-02; Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma 4 on 2026-09-14; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-07-13; Total score [MoCA] 26 on 2026-07-13 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetes | active | confirmed | E11.65 | S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic. |
| Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressure | active | confirmed | I10 | S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life. |
| Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluated | resolved | confirmed | R74.01 | S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis. |
| Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcohol | active | confirmed | K76.0 | S — Synthetic modern diagnosis. Not part of the public record of his life; chosen to teach surveillance. |
| Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh A | active | confirmed | K74.69 | S — Synthetic modern diagnosis. Not part of the public record of his life; the liver cancer diagnosed three years later in the true frame does not appear in the modern episode. |
| Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statin | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Obesity, class 1 (BMI 31.4) | active | confirmed | E66.811 | S — Synthetic finding; described without stigma. |
| Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30 | active | confirmed | H54.62 | S — Synthetic modern measurement anchored to the documented cataract in his left eye. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-16 | Hemoglobin A1c/Hemoglobin.total in Blood | 8.4 | % | Below 5.7% is normal; goal below 7% for him | High | S |
| 2026-02-16 | Glucose [Mass/volume] in Serum or Plasma | 168 | mg/dL | 70-99 mg/dL | High | S |
| 2026-02-16 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-16 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-16 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 77 | mL/min/{1.73_m2} | 60 or higher without kidney damage markers is not CKD | Normal | S |
| 2026-02-16 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | Below 30 mg/g is normal (A1) | Normal | S |
| 2026-02-16 | Cholesterol [Mass/volume] in Serum or Plasma | 212 | mg/dL | <=199 mg/dL | High | S |
| 2026-02-16 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 132 | mg/dL | Goal below 70 mg/dL with diabetes and other risk factors | High | S |
| 2026-02-16 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 38 | mg/dL | >=40 mg/dL | Low | S |
| 2026-02-16 | Triglyceride [Mass/volume] in Serum or Plasma | 210 | mg/dL | <=149 mg/dL | High | S |
| 2026-02-16 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 | U/L | 10-40 U/L | High | S |
| 2026-02-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 42 | U/L | 7-55 U/L | Normal | S |
| 2026-02-16 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 | U/L | 40-129 U/L | Normal | S |
| 2026-02-16 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-02-16 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-02-16 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-02-16 | Platelets [#/volume] in Blood by Automated count | 138 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-02-16 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 340 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-02-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-02-16 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-03-02 | Liver stiffness by US.transient elastography | 17.6 | kPa | Below 8 kPa makes advanced fibrosis unlikely; 15 kPa or higher is consistent with compensated advanced chronic liver disease | High | S |
| 2026-03-02 | INR in Platelet poor plasma by Coagulation assay | 1.1 | {INR} | 0.8-1.2 | Normal | S |
| 2026-03-02 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 4.2 | ng/mL | <=8.3 ng/mL | Normal | S |
| 2026-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 75 | mL/min/{1.73_m2} | 60 or higher without kidney damage markers is not CKD | Normal | S |
| 2026-04-13 | Cholesterol [Mass/volume] in Serum or Plasma | 148 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-04-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 | mg/dL | Goal below 70 mg/dL with diabetes and other risk factors | Normal | S |
| 2026-04-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 40 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-04-13 | Triglyceride [Mass/volume] in Serum or Plasma | 168 | mg/dL | <=149 mg/dL | High | S |
| 2026-04-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 | U/L | 10-40 U/L | High | S |
| 2026-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 40 | U/L | 7-55 U/L | Normal | S |
| 2026-05-18 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.3 | % | Below 5.7% is normal; goal below 7% for him | High | S |
| 2026-07-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-07-13 | Total score [MoCA] | 26 | {score} | S | ||
| 2026-09-14 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.8 | % | Below 5.7% is normal; goal below 7% for him | High | S |
| 2026-09-14 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-14 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 1.06 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 78 | mL/min/{1.73_m2} | 60 or higher without kidney damage markers is not CKD | Normal | S |
| 2026-09-14 | Albumin/Creatinine [Mass Ratio] in Urine | 14 | mg/g | Below 30 mg/g is normal (A1) | Normal | S |
| 2026-09-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 10-40 U/L | Normal | S |
| 2026-09-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-55 U/L | Normal | S |
| 2026-09-14 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-09-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-09-14 | Platelets [#/volume] in Blood by Automated count | 140 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-09-14 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 4 | ng/mL | <=8.3 ng/mL | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-16 | Body height | 182 | cm | S |
| 2026-02-16 | Body weight | 104 | kg | S |
| 2026-02-16 | Body mass index (BMI) [Ratio] | 31.4 | kg/m2 | S |
| 2026-02-16 | Systolic blood pressure | 152 | mm[Hg] | S |
| 2026-02-16 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 2026-02-16 | Heart rate | 76 | /min | S |
| 2026-02-16 | Respiratory rate | 16 | /min | S |
| 2026-02-16 | Body temperature | 36.7 | Cel | S |
| 2026-02-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-03-02 | Body height | 182 | cm | S |
| 2026-03-02 | Body weight | 103.6 | kg | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 31.3 | kg/m2 | S |
| 2026-03-02 | Systolic blood pressure | 148 | mm[Hg] | S |
| 2026-03-02 | Diastolic blood pressure | 90 | mm[Hg] | S |
| 2026-03-02 | Heart rate | 74 | /min | S |
| 2026-03-02 | Respiratory rate | 16 | /min | S |
| 2026-03-02 | Body temperature | 36.6 | Cel | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-04-13 | Body height | 182 | cm | S |
| 2026-04-13 | Body weight | 101.8 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 30.7 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 72 | /min | S |
| 2026-04-13 | Respiratory rate | 16 | /min | S |
| 2026-04-13 | Body temperature | 36.7 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-18 | Body height | 182 | cm | S |
| 2026-05-18 | Body weight | 99.9 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 30.2 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 74 | /min | S |
| 2026-05-18 | Respiratory rate | 16 | /min | S |
| 2026-05-18 | Body temperature | 36.6 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-14 | Body height | 182 | cm | S |
| 2026-09-14 | Body weight | 97.2 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 29.3 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 72 | /min | S |
| 2026-09-14 | Respiratory rate | 16 | /min | S |
| 2026-09-14 | Body temperature | 36.7 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-13 | Body height | 182 | cm | S |
| 2026-07-13 | Body weight | 98.6 | kg | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 29.8 | kg/m2 | S |
| 2026-07-13 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-07-13 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-07-13 | Heart rate | 72 | /min | S |
| 2026-07-13 | Respiratory rate | 16 | /min | S |
| 2026-07-13 | Body temperature | 36.6 | Cel | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-02-16 | Establishing primary care for type 2 diabetes and high blood pressure above goal: A1c, kidney function, urine albumin, lipids, the yearly liver check with FIB-4, eyes, feet and brain health in a former professional boxer | finished | S |
| 2026-03-02 | Two-week review of home blood pressure readings, with liver elastography, a liver ultrasound and the hepatology consultation | finished | S |
| 2026-04-13 | Eight-week review: blood pressure, lipids, kidney function, semaglutide, the endoscopy result and vaccines | finished | S |
| 2026-05-18 | Three-month review: A1c, blood pressure, weight, semaglutide dose and the eye examination | finished | S |
| 2026-09-14 | Seven-month review: six-month liver cancer surveillance ultrasound and AFP, A1c, kidney function, urine albumin and vaccines | finished | S |
| 2026-07-13 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Diabetes: continue metformin, an A1c every three months until at goal and then every six months, diabetes self-management education, a vitamin B12 check on long-term metformin, and no medicine that causes low blood sugar | completed | GL-ADA-PHARM-2026, GL-CMID-2026 | S |
| Hepatology consultation for a high FIB-4 with mildly low platelets, with transient elastography and a liver ultrasound the same day | completed | GL-AASLD-MASLD-2023, GL-ADA-COMORB-2026 | S |
| Liver assessment: FIB-4 from the yearly liver tests, then transient elastography if FIB-4 is 1.3 or higher; hepatitis B, hepatitis C and HIV tests, iron studies, and an alcohol history | completed | GL-AASLD-MASLD-2023, GL-ADA-COMORB-2026, GL-CMID-2026 | S |
| Compensated cirrhosis: liver ultrasound with AFP every six months for hepatocellular carcinoma surveillance, upper endoscopy to screen for varices, hepatitis A and B and pneumococcal vaccines, no alcohol, no NSAIDs, acetaminophen no more than 2 g a day, and teaching on the warning signs of decompensation | completed | GL-AASLD-HCC-2023, GL-BAVENO-VII, GL-AASLD-MASLD-2023, GL-CDC-IMZ-2026 | S |
| Semaglutide once weekly, increased every four to eight weeks as tolerated, for its cardiovascular and kidney benefit, weight and steatotic liver disease; prior authorization and the manufacturer's assistance program handled by the clinic | completed | GL-ADA-PHARM-2026, GL-ADA-COMORB-2026, GL-AASLD-MASLD-2023 | S |
| Blood pressure: a validated home monitor with a large cuff, readings twice a day for a week, a goal below 130/80 mmHg, and less salt | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Amlodipine added to lisinopril and increased to reach the goal, with ankle-swelling checks | completed | GL-AHA-HTN-2025, GL-ADA-CVD-2026 | S |
| Cardiovascular risk: atorvastatin 40 mg with a lipid panel at four to twelve weeks; a baseline ECG; aspirin for primary prevention not used because of bleeding risk | completed | GL-ADA-CVD-2026, GL-CMID-2026 | S |
| Kidneys: eGFR by the race-free CKD-EPI 2021 equation and urine albumin-to-creatinine ratio at least yearly, and potassium and creatinine on lisinopril | completed | GL-ADA-CKD-2026, GL-CMID-2026 | S |
| Eyes and feet: a dilated eye examination at the eye clinic, a comprehensive foot examination yearly, daily foot checks and callus care | completed | GL-ADA-RETFOOT-2026 | S |
| Brain health: a documented cognitive screen at the preventive visit, blood pressure and glucose control, sleep, hearing and mood checks, and an honest conversation that chronic traumatic encephalopathy cannot be diagnosed during life | completed | GL-NINDS-TES-2021, GL-CMID-2026 | S |
| Cost and access: low-cost generics, 90-day supplies, and help with coverage for any brand-name medicine | completed | GL-ADA-POP-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| A1c below 7% within six to nine months, without low blood sugar | 2026-09-14 | completed | 8.4% to 6.8% at seven months; no low blood sugar | S |
| Blood pressure below 130/80 mmHg in the clinic and at home | 2026-09-14 | completed | 122/76 in the clinic; home average 124/78 | S |
| LDL cholesterol below 70 mg/dL | 2026-04-13 | completed | 132 to 68 mg/dL on atorvastatin | S |
| Weight loss of 7 to 10% for liver health within a year | 2026-09-14 | active | 104.0 to 97.2 kg (6.5%) at seven months | S |
| Liver cancer surveillance by ultrasound with AFP every six months, on time | 2026-09-14 | completed | Baseline and six-month ultrasounds with AFP on schedule; no focal lesion; AFP 4.2 and 4.0 ng/mL | S |
| No alcohol, to protect the liver | 2026-09-14 | completed | No alcohol since the two-week visit | S |